Akebia Therapeutics
AKBA
139 hedge funds and large institutions have $399M invested in Akebia Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 39 reducing their positions, and 22 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 39
18% more capital invested
Capital invested by funds: $339M → $399M (+$60.8M)
0.8% more ownership
Funds ownership: 65.51% → 66.31% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 145 → 139 (-6)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
39% less call options, than puts
Call options by funds: $2.3M | Put options by funds: $3.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$13.8M |
| 2 |
JP Morgan Chase
New York
|
+$12.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.34M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.27M |
| 5 |
BlackRock
New York
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.2M |
| 2 |
Millennium Management
New York
|
-$3.65M |
| 3 |
Morgan Stanley
New York
|
-$2.29M |
| 4 |
Two Sigma Investments
New York
|
-$2.12M |
| 5 |
Two Sigma Advisers
New York
|
-$2.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QC
151
QCM Cayman
Houston,
Texas
| – | -$41K | -12,059 | Closed |
|
|
LSA
152
Leonteq Securities AG
Zurich,
Switzerland
| – | -$16.9K | -5,000 | Closed |
|
153
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$12K | -3,878 | Closed |
|
154
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -280 | Closed |
|
|
MAM
155
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -270 | Closed |
|
|
DI
156
Disciplined Investments
Tulsa,
Oklahoma
| – | -$1K | -187 | Closed |
|
157
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$74 | +22 | New |
|
|
FWM
158
Focused Wealth Management
Newburgh,
New York
| – | +$219 | +65 | New |
|
|
IA
159
IFP Advisors
Tampa,
Florida
| – | +$343 | +102 | New |
|
AKBA Hedge Fund Activity: Q2 2021 in Review
139 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2021, worth a combined $399M — up 18% from $339M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AKBA and 17 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 53 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $13.8M. The largest seller was State Street, cutting an estimated $10.2M.
- 139 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2021, down from 145 in Q1 2021.
- Funds reported $399M of Akebia Therapeutics stock for Q2 2021, up 18% quarter-over-quarter.
- 17 funds opened new Akebia Therapeutics positions in Q2 2021 and 22 closed out, a net change of -5 holders.
- The largest Akebia Therapeutics buyer in Q2 2021 was Marshall Wace, an estimated $13.8M added.
- The largest Akebia Therapeutics seller in Q2 2021 was State Street, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2021.